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Abstract  
The aim of this study was to evaluate a novel combination of hydroxypropyl methylcellulose 
phthalate (HPMCP-HP-50) and Soluplus® polymers for enhanced physicochemical stability and 
solubility of the produced amorphous solid dispersions (ASDs). This was achieved using hot melt 
extrusion (HME) to convert the crystalline active pharmaceutical ingredient (API) into a more 
soluble amorphous form within the ternary systems. Itraconazole (ITZ), a Biopharmaceutics 
Classification System class II (BCS II) API, was utilized as the model drug.  The extrudates were 
characterized by Powder X-Ray diffraction (PXRD), Differential Scanning Calorimetry (DSC), 
Thermogravimetric Analysis (TGA), Fourier Transform Infrared (FTIR) spectroscopy, Solid State 
Nuclear Magnetic Resonance (ssNMR) and dissolution studies.   The data showed that the ASDs 
were physically and chemically stable at 20°C and 50% RH over 12 months. PXRD results 
indicated that the ITZ in the ASDs was in the amorphous state and no recrystallization occurred. 
DSC scans confirmed that each formulation exhibited a single intermediate glass transition (Tg), 
around 96.4 °C, indicating that ITZ was completely miscible in the polymeric blends of HPMCP 
and Soluplus® at up to 30% (w/w) drug loading and that the two polymers were miscible with 
each other in the presence of ITZ. The FTIR analysis indicated the formation of strong hydrogen 
bonding between ITZ, HPMCP and Soluplus®. The dissolution end-point of the ASDs was 
determined to be approximately 10 times greater than that of the crystalline ITZ.  
 
Key words: Itraconazole; Physical Stability; Enhanced Solubility; Analytical Techniques; 
Dissolution studies. 
1. Introduction 
Amorphous solid dispersions are an increasingly popular strategy for improving the 
bioavailability of poorly soluble APIs (Abraham and Crull, 2014; Guns et al., 2011). In these 
ASDs, the API exists at a higher Gibbs free energy than the stable crystalline form, has a greater 
surface area and is intimately mixed with the carrier (usually a polymer).  A hydrophilic polymer 
is frequently used to prevent crystallization and precipitation of the drug in ASD, and it therefore 
retains a high supersaturation level in the gastrointestinal tract. In spite of years of research in the 
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area, only around 15 commercial products (e.g., Kaletra®, Belsomar®, Noxafil®, and Harvoni®) 
that use the ASD technique are available on the market (Meng et al., 2017). This is due to the 
tendency of such systems towards spontaneous crystallisation and the perception that crystalline 
drug products are less risky (Davis et al., 2016).  There are many standards of a successful 
commercial ASD, and it is possible that a single polymer will not fulfil all requirements. Also, the 
processing/optimization of these amorphous dispersions remains a key challenge. Recently, it has 
been demonstrated that ternary ASDs, which contain a mixture of two polymers, can be more 
physically stable and less prone to API recrystallization than binary compositions (Bi et al., 2013; 
Prasad et al., 2014).   
Itraconazole (ITZ), a potent anti-fungal drug, was selected as a model drug in this study. It has 
very low aqueous solubility, approximately 1 ng/mL at pH 7 and 4 µg/mL at pH 1 (Peeters et al., 
2002), it is highly lipophilic (cLogP 6.2) and weakly basic (pKa values 2 and 4) but demonstrates 
excellent biological membrane permeability (Brouwers et al., 2017). Separate studies have 
attempted to increase the bioavailability of ITZ by using spray drying (Kumar et al., 2014), hot 
melt extrusion (HME) (Janssens et al., 2008; Thiry et al., 2017; Verreck et al., 2003), and 
crystalline ITZ nanoparticles (Yang et al., 2010b). A previous study by our group showed that 
combinations of HPMCP and Soluplus® have a significant effect on the stability of spray dried 
ITZ against recrystallization (Davis et al., 2017). HME,  a continuous and solvent-free processing 
method, employed for the preparation of ASDs has advanced as a trustworthy, scalable processing 
technology in the pharmaceutical industry (Douglas et al., 2016a; Douglas et al., 2016b; Radl et 
al., 2010). It has been used to prepare different dosage forms, such as; implants, tablets, process 
intermediates for controlled release and solubility enhancement of therapeutics (Keen et al., 2014; 
Lenz et al., 2017), with acceptable process scale-up and product quality control via process 
analytical technology (PAT).  Rapid physical changes are likely to occur during HME, where the 
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drug is intensively mixed, heated and conveyed through the extrusion barrel and then cooled to 
solidify at ambient temperature (Jani and Patel, 2015). So, HME of ITZ may produce liquid 
crystalline ITZ rather than amorphous ITZ (Singh et al., 2016).  
The main aim of this study was to use HME to prepare novel ternary ASDs of ITZ with 
enhanced aqueous solubility and physical stability. Both HPMCP and Soluplus® have been used 
individually as polymeric carriers for extruded ITZ ASDs. However, to our knowledge, the use 
of a combination of both polymers has not been prepared by HME previously. The model system 
chosen was ITZ-HPMCP-Soluplus®. HPMCP is largely water insoluble (at low pH) so HPMCP 
bound drug will release in the intestine (it is an enteric polymer) and Soluplus® bound drug will 
release in the stomach. HPMCP was  selected for its ability to stabilise ITZ in the amorphous state 
through hydrogen bonding. Soluplus® was  also chosen to enhance stability and make processing 
by HME possible. A Design of Experiment (DoE) approach was employed to optimize the 
formulation (Table 1). Detailed physiochemical characterizations using several analytical 
techniques such as PXRD, DSC, TGA, FTIR spectroscopy and ssNMR were performed to 
understand the drug-polymer-polymer molecular interactions, confirm the state of ITZ and 
compare the results with the formerly prepared spray dried formulations. This was supported by 
dissolution studies after storage for 12 months.  
2. Materials and Procedures 
2.1. Materials  
Itraconazole was purchased from Xi'an Lyphar Biotech Co., Ltd (Xi'an City, China). Shin Etsu, 
Tokyo, Japan donated hydroxypropyl methylcellulose phthalate, HP-50 grade (HPMCP)) and 
Soluplus® was donated by BASF, Ireland.  
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2.2. Preparation of ITZ ASD by hot melt extrusion 
A user-defined Design of Experiment (DoE, Design-Expert® Software Version 10 - Stat-Ease, 
Cambridge, United Kingdom) was employed to study the effect of formulation variables (17 
combinations: Table 1) on the properties of the extruded ASD and provide information on the 
most effective API-polymer ratios through systematic screening. Drug loading ranged from 10 – 
30% (w/w) and HPMCP/Soluplus® ratios varied from 30 – 60% (Table 1). 
  The ternary solid dispersions were prepared by HME using a 16 mm pharma-lab co-rotating 
twin screw extruder and L/D ratio of 40:1 (Thermo Fisher Scientific, Karlsruhe, Germany; located 
at the University of Bradford, UK). The drug and polymers were physically mixed in a 
polyethylene bag and manually fed into the hopper, while monitoring the motor torque. The 
processing screw rate was set at 50 rpm and temperatures of the nine-heated barrel and die zones 
were set as follows: zone 1 = 90 °C, 2 to 4 = 130 °C, 5 to 6 = 155 °C and 7 to 9 = 165 °C. A die 
with 2.5 mm diameter was fitted at the end of the barrel. After cooling at ambient conditions, the 
extrudates were milled for a short period of time to avoid heating of the samples (1 to 3 min)  
using a Mixer Mill, MM 400 (Retsch GmbH, Germany) at 20 Hz frequency, then passed through 
sieves (particles with diameter < 100 μm were collected) and stored (room conditions: 
∼20°C/50% RH) in glass vessels inside a desiccator for further analysis. The DSC analysis 
confirmed that it is not possible to prepare ASDs of ITZ/HPMCP/Soluplus® using ball milling 
only (data not shown here).  
2.3. Characterisation of ITZ ASDs and pure polymers 
2.3.1. Thermogravimetric Analysis (TGA)  
TGA was completed using a PerkinElmer TGA 4000 at a heating rate of 10 ºC/min from 20 ºC 
to 300 ºC under nitrogen purging (50 mL/min). A typical sample weight was 10 mg.   
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2.3.2. Powder X-Ray Diffraction (PXRD) 
PXRD studies of samples were performed before and after storage for 12 months using an 
Empyrean PANalytical Almelo (The Netherlands) in reflection mode with samples mounted on a  
spinner configuration using zero background discs.  X-rays were generated using Cu anode 
material and K-α wavelength of 1.5406 Å. The 2θ angle range, step size and dwell time were 
5−30°, 0.05°, and 2s, respectively.  
2.3.3. Differential Scanning Calorimetry (DSC) 
DSC studies were conducted on a Perkin Elmer DSC 8500 equipped with a refrigerated cooling 
accessory (PerkinElmer, UK). Helium (30 mL/min) was used as the purge gas. The instrument 
was calibrated using heating rates of 100 and 200 °C/min using high purity indium and zinc to 
standardize the temperature and heat flow signals. For the glass transition measurement, 
phosphorus-pentoxide was placed at the bottom of the desiccators to rigorously dry the samples 
before measurements.  2.0 − 5.0 mg samples were weighed and placed in crimped DSC pans. 
Samples were ramped from 0 to 180 °C at 100 °C/min to determine the melt endotherm, or 200 
°C/min to study the glass transition region. Analyses was carried out in triplicate using 
PerkinElmer Pyris thermal analysis software (version 10.1).   
2.3.4. Fourier Transform Infrared (FTIR) analysis 
FTIR spectra were recorded using an Agilent Cary 630 FTIR spectrometer in the range of 
4000–650/cm. Spectra were reordered using attenuated total reflectance (ATR) FTIR, enabling a 
direct measurement on the sample without dilution in KBr discs. 
2.3.5. Solid State Nuclear Magnetic Resonance (ssNMR) spectroscopy 
Carbon-13 ssNMR spectra were acquired on a Bruker Avance III HD NMR spectrometer 
operating at B0 = 9.4 T, with corresponding 1H and 13C resonance frequencies of ν0(1H) = 400.1 
MHz and ν0(13C) = 100.6 MHz.  Samples of ITZ, HPMCP-HP50, and Soluplus® were packed in 
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4 mm o.d. zirconia rotors with Kel-F caps under ambient atmosphere, and experimental 13C NMR 
spectra were acquired at natural abundance using a 4 mm double channel (X/H) Bruker MAS 
probe.  A contact time of 4 ms was optimized using a crystalline sample of ITZ and was used for 
the acquisition of all 13C CP/MAS NMR spectra. Tetramethylsilane was used as shift reference. 
2.4. HPLC method and Dissolution studies 
High Performance Liquid Chromatography (HPLC) analysis was performed using an Agilent 
1260 Infinity series system (Agilent Technologies, Waldbronn, Germany) equipped with a 
G1311B 1260 quaternary pump, G1329B 1260 auto-sampler, vacuum degasser and G1316A 1260 
temperature-controlled column compartment maintained at 25 °C. The samples were analysed 
with HPLC at λ = 263 nm using a new method developed for the study and this was accurate and 
precise for quantification of ITZ in solution along with HPMCP and Soluplus® (method validation 
will be described in section 3.8). Four stock solutions of ITZ (250 µg/mL) were prepared in 70% 
(v/v) acetonitrile and 30% (v/v) de-ionized water (pH 3 adjusted using ortho-phosphoric acid). 
One of the solutions also contained Soluplus® (1500 µg/mL), one HPMCP (1500 µg/mL) and one 
with both polymers. A calibration curve was produced using each of the four solutions by 
continual 1:1 dilution of each solution with mobile phase until no measurable response was 
attained. Following each dilution, the samples were mixed by vortex, passed through a syringe 
filter and transferred to amber glass vials until further analysis by HPLC. 
A Kromasil C18 5 μm, 4.6 d 250 mm column (MZ-Analysentechnik GmbH, Mainz-Germany) 
was attached and a  flow rate of 1 mL/min was used.  An isocratic run, having a total run time of 
12 min, was sufficient to separate the ITZ. Typical injection volume was 10 μL. ITZ was detected 
at a retention time equivalent to 8.8 min at a wavelength of 263 nm. Prior to sample analysis, the 
developed HPLC method was validated through the evolution of method development and 
validation parameters including specificity, linearity, precision, limit of detection and limit of 
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quantification.  Specificity of the method and peak interference was investigated by injecting a 
placebo with no ITZ content and no interfering peaks were observed. 
Drug release studies were carried out for the ternary ASDs in 900 mL simulated gastric fluid, 
SGF, (hydrochloric acid at pH 1.2) (Bagavatula et al., 2014) using USP type II apparatus with a 
paddle speed of 100 rpm at a temperature of 37 ± 0.2 °C. The ASD powders (all containing 150 
mg of ITZ) were added to the dissolution medium and 2.5 mL aliquots were withdrawn from each 
vessel at predetermined time intervals (12, 30, 45 min and 1, 2, 3, 4, 5 and 6 h) with instantaneous 
replacement of the equivalent volume of the fresh dissolution medium. The samples were passed 
through a 0.45 µm syringe filter (Teflon) with the first 1 mL of each sample being discarded. A 
100 µL aliquot was immediately diluted with 900 μL of the mobile phase to avoid precipitation 
of the drug.  
3. Results and Discussion 
3.1. Rationale for polymers selection 
The selection of HPMCP and Soluplus® was based on some key considerations. Firstly, the 
ease of extrusion of Soluplus® due to its thermoplastic and rheological properties. Extrusion of 
HPMCP and ITZ without Soluplus® was not possible and degradation occurred before the 
materials exhibited sufficient thermo-plasticisation for extrusion. However Soluplus®, with its 
low bulk density and excellent flow properties, has been particularly developed for HME 
processing with remarkable capabilities for solubilisation of BCS class (II) and a wide possibility 
of making ASDs (Kolter et al., 2012). In this study, the addition of Soluplus® lowered the viscosity 
of the extrudates, resulting in easier flow of the formulation through the barrel and screws and 
enabled the extrusion of ternary mixtures containing up to 30% (w/w) ITZ and 40% (w/w) 
HPMCP. Secondly, it meant that the formulation contained one stabilising polymer (HPMCP) and 
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one stabilising/solubility enhancing polymer (Soluplus®), which will encourage hydrophobic 
interactions with ITZ. Thirdly, the potential existed for hydrogen bonding or other intermolecular 
interactions between polymeric components. The chemical structures of ITZ, HPMCP and 
Soluplus® are illustrated in Figure 1. It is apparent that Soluplus® has several H-bond acceptor 
sites while HPMCP has both H-bond donors and acceptors.  ITZ, a weak base, can form hydrogen 
bonds with the carboxylate groups in HPMCP and also form π-π interactions with the aromatic 
portions of the phthalate groups in HPMCP.  HPMCP has a greater stabilising effect on ITZ than 
Soluplus® due to its higher Tg and tendency to form hydrogen bonds with ITZ.  However, in 
comparison to formulations prepared by spray drying, it is anticipated that both HPMCP and 
Soluplus® will form stronger bonds with the ITZ due to the intense mixing/heating during the 
HME processing (Davis et al., 2017). As a result, the ITZ can embed itself into the porous structure 
of the amorphous HMPCP, thus protecting the drug from recrystallization. In addition, compounds 
are deemed immiscible if the difference in their Hansen’s solubility parameters is greater than 7 
MPa1/2 (Greenhalgh et al., 1999). The previously reported solubility parameters for Soluplus® and 
HPMCP are 23.4 and 22.4 MPa1/2, respectively, which are very similar to that of ITZ; 22.6 MPa1/2 
(Piccinni et al., 2016), supporting the suggestion that the ITZ, HPMCP and Soluplus® are 
miscible.   
3.2. Design of experiment (DoE) results 
DoE was used to provide a systematic way of selecting the drug-polymer ratios while 
minimizing the number of formulations required for a statistical analysis. The three factors 
considered were based on weight percentages (% w/w) of the formulation components: factor A: 
ITZ; factor B: Soluplus®; and factor C: HPMCP.  Formulation parameters were as follows: 10% 
≤ A ≤ 30%, Soluplus® or HPMCP 30% ≤ B/C ≤ 60%; to guarantee that the experimental design 
space comprises of therapeutically applicable quantities of drug.  On the basis of comparison of 
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statistical indices for model adequacy, a linear model was selected and a brief description of the 
results obtained is illustrated in Figure 2.  The responses were recorded and analysis of data was 
carried out using ANOVA. Response: Tg (°C) in ANOVA; values of "Prob > F" less than 0.0500 
indicate model terms are significant. The Model F-value of 20.72 implies the model is significant.  
There is only a 0.01% chance that a "Model F-Value" this large could occur due to noise. Final 
model equation in terms of actual components:  
HPMCPSoluplusITZT g 57.12312.8275.68     [1] 
The predicted R2 of the model was 0.6891 and in reasonable agreement with the R2Adj of 0.7848 
(Please see supplementary data, SD2).  From Figure 2 and the model equation, it is clear that the 
Tg largely increases with the increase of the content of HPMCP (higher positive coefficient value) 
and that the lowest value of Tg was obtained for the samples containing the highest ratios of ITZ 
and Soluplus® e.g. sample 6, 10, 11, 12 and 17. 
3.3. Thermal stability and processing temperatures 
It is essential when producing ASDs using HME to ensure that the API and excipients are 
thermally stable at the temperatures of manufacturing. The thermal degradation temperatures, 
measured by TGA for each individual ingredient, were  ITZ at 250 °C, Soluplus® at 250 °C and 
HPMCP at 195 °C, however, parallel trials for Soluplus® alone indicated that temperatures above 
170 °C are responsible for a subtle colour change in the extrudate, probably due to partial 
degradation of Soluplus®. The same trial also indicated that the minimum processing temperature 
for Soluplus® was 120 °C so the temperature range for HME zones was selected as 130 °C to 
165 °C.  
3.4. Analysis of crystallinity, PXRD  
The crystalline nature of pure ITZ was demonstrated by PXRD patterns with characteristic 
Bragg peaks at 14.5, 17.7, 20.5, 23.6, 25.5 and 27.3 (Figure 3). The patterns were very similar to 
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those reported in previous studies (Lang et al., 2014).  Conversely, excipient polymers exhibited 
characteristic broad amorphous halos. All formulations of ITZ/HPMCP/Soluplus® at various 
loadings (10 to 30% (w/w) ITZ) were PXRD amorphous after extrusion (day one for selected 
formulations). Furthermore, all formulations remained PXRD amorphous after 12 months of 
storage. The excellent stability of the formulation is likely due to intermolecular interactions 
between HPMCP/Soluplus® and ITZ.  The carboxylate groups within HPMCP can hydrogen bond 
with the ternary amine groups in ITZ. Also, π-π stacking between the phthalate groups in HPMCP 
and the aromatic rings in ITZ could enhance intermolecular attraction further.  The FDA stability 
guidance of storage at 40 oC and 75% RH is minimum of 6 months. This indicates that the new 
ternary solid dispersion composition developed in this study demonstrates excellent physical 
stability upon storage and can inhibit the recrystallization of ITZ more efficiently than some 
binary/ternary solid dispersion compositions reported in literature (Alia A. Badawi et al., 2011; 
Thiry et al., 2016).  However, variation in the drug loading, polymers used and processing 
methods should be considered for direct comparison.  
3.5. Thermal analysis, DSC  
It is known that the limit of detection of small portions of crystallinity in a mainly amorphous 
matrix by PXRD is in the range of a few percent crystallinity by mass (Newman et al., 2015). So, 
further characterisation was carried out using DSC. Pure crystalline ITZ exhibited a sharp melting 
endotherm with an onset of 169.46 ± 2.89 °C and a heat of fusion of ΔH = 86.94 ± 3.21 J/g. 
Soluplus® and HPMCP had Tg temperatures of 82.13 ± 2.05 and 147.56 ± 1.49 °C respectively, 
confirming their amorphous state (Figure 4). Technical data sheets for the two polymers suggest 
glass transition temperatures of 70 and 145 °C for Soluplus® and HPMCP, respectively, so the 
measured glass transition, especially for Soluplus®, is much higher than expected. Glass transition 
is a structural relaxation governed by a relaxation time, τ. As the thermal conductivities of these 
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polymers are not equal to infinity, there is a lag in the flow of heat through the material during 
glass transition. Therefore, if the heating rate is increased in magnitude, the available relaxation 
time is smaller and the transition is shifted to a higher temperature (Moynihan et al., 1974). 
However, it is interesting that the dependence of the Tg of Soluplus® on heating rate is much 
greater than that of HPMCP. While thermal conductivity data is not available for these polymers 
we suggest that the molecular weight of the former being around double that of the latter could be 
a factor. The quench-cooled ITZ sample, prepared by placing ITZ on a stainless steel hotplate and 
heating until completely melted before rapidly quenching and grinding in liquid nitrogen exhibited 
a glass transition at 58.99 ± 0.87 °C (Knapik et al., 2016). In addition to a Tg, the quench-cooled 
ITZ displayed two endothermic transitions attributed to the presence of liquid crystals (LCs) (Six 
et al., 2001). The two transitions of liquid crystalline ITZ, TLC1 and TLC2, are located at 74 °C 
and 90 °C, respectively. This phase transition has been previously reported and confirmed (Singh 
et al., 2016). The absence of these endotherms or phase transitions due to liquid crystals in the 
HME samples indicated that they contained a completely amorphous drug.  The DSC scans for 
ITZ formulations after 12 months of storage at 25°C and 50% RH are illustrated in Figure 4, and 
the measured and predicted Tg values are summarised in Table 1. Each formulation exhibited a 
single glass transition value regardless of the ratio (Table 1), indicating that the ASDs are present 
as a homogenous single phase, amorphous drug-polymer-polymer solid dispersion. The ASDs of 
ITZ prepared by spray drying in our previous study showed two glass transitions corresponding 
to HPMCP-rich and Soluplus®-rich amorphous drug phases (Davis et al., 2017). A single glass 
transition is preferred in an ASD and therefore, it can be concluded that HME has an advantage 
over spray drying in preparing the system under investigation by producing more homogenous 
dispersions and stronger intermolecular interactions. 
  
14 
 
Theoretical glass transition temperature for each ternary mixture (Tg,mix) was calculated using 
the Couchman–Karasz (C-K) (Eq. 2) for ternary systems (Couchman and Karasz, 1978):  
332211
333222111
PPP
gPgPgP
g CxCxCx
TCxTCxTCx
T


                                        [2] 
where xi is the mass fraction and ΔCpi is the heat capacity change when crossing from the glass 
to the rubber state in component i and 1, 2 and 3 refer to the three components (3 is assigned to 
the component with the lowest Tg). The heat capacity change (ΔCp) for pure amorphous ITZ at 
the Tg was 0.32 J/g°C, and for HPMCP and Soluplus® equal to 0.31 J/g°C and 0.22 J/g°C, 
respectively. 
From Table 1, the formulations with the highest HPMCP content have the highest Tg values. 
The average of  the Tg values of all formulations was 96.4 °C while the average difference between 
measured and predicted is 9.7°C. Konno et al. employed the C-K equation to estimate the 
predicted Tg for Felodipine with poly(vinylpyrrolidone) (PVP), hydroxypropylmethyl cellulose 
acetate succinate (HPMCAS), and hydroxypropylmethyl cellulose (HPMC), and the largest 
deviation between the estimates across the entire range for these three systems was ~8°C (Konno 
and Taylor, 2006). The greater difference between predicted and measured Tg values for the 
ternary system highlights the more complex task of predicting the behaviour of these mixtures 
over binary. The C-K model describes an ideal situation and are simple weight proportionality 
functions assuming an ideal volume of mixing and a lack of molecular interactions. Typically, 
deviations from the C-K are therefore explained in terms of entropy changes or the presence of 
molecular interactions. Negative volume of mixing (densification) and strong exothermic or 
favourable interactions result in a positive deviation of Tg from the model due to a reduction in 
free volume (Shen and Torkelson, 1992).  
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Conversely, any increase in free volume will act to produce a negative deviation of glass 
transition temperature from the model. Pennacchia et al. (1986) observed that local compositional 
fluctuations can also contribute to positive or negative deviations (Pennacchia et al., 1986). In the 
case presented here, all experimental Tg values negatively deviated from the predicted values. 
However, the interactions between ITZ and polymers in the ternary system are very complex, 
attributable to the large number and variety of functional groups and size of the polymers where 
a huge number of intermolecular association permutations are possible.  
3.6. FTIR spectroscopy 
The FTIR spectra (Figure 5) of the raw materials and selected ASD 15 are displayed. In Figure 
5 the IR region from 1300/cm to 600/cm is the fingerprint region for ITZ. The peak at 1379/cm is 
assigned to an ether linkage, R–O–R. Peaks at 1509/cm and 1551/cm are related to R–C=C 
bonding, and R–C–C bonding, respectively. Peaks at 1451 and 1609/cm are due to the C‒N and 
C=N bonds, respectively and the sharp peak observed at 1697/cm is caused by ‒C=O stretch of 
the triazol-3-one moiety in the ITZ (Singh et al., 2016). The absorption bands between 2831/cm 
and 3200/cm are attributed to the stretching vibration of (‒CH3(vC‒H) and amine groups in ITZ 
(Shim et al., 2006). For Soluplus®, peaks around 1638/cm and 1733/cm are related to the carbonyl 
groups in the vinyl acetate and caprolactam segments (Semjonov et al., 2016) and a single 
carbonyl peak was detected at 1724/cm for HPMCP.    
Soluplus® low intensity peak for –OH stretching was observed at 3450/cm. The IR spectra of 
solid dispersion (ASD 15) shown in Figure 5) showed that none of the characteristic peaks of ITZ 
are evident, confirming the full miscibility of ITZ in the binary polymeric matrix. Among the 
most distinguished band disappearance happened at 1697/cm (C=O), 1609/cm (C=N), and 
1380/cm (C–H of the methyl group) (Yang et al., 2010a). Also, the disappearance of the ‒C=O 
stretch of the triazol-3-one at 1697/cm indicates the formation of H-bonding. Changes in the 
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intensity and position of the absorption band at 2831/cm indicate more chemical interactions 
between Soluplus® and ITZ (Zhang et al., 2013). 
Hydrogen bonding in the ternary system will occur between the nitrogen indicated by the arrow 
in the insert and the carboxylic acid groups in HPMCP. Evidence for hydrogen bonding can be 
seen by comparing the FTIR spectra of ITZ crystalline with ASD 15. The imine (C=N) stretch 
present in ITZ crystalline as a strong sharp peak at 1554 cm/cm is absent in ASD 15, indicating 
that the C=N bond is no longer able to stretch (due to hydrogen bonding). ASD 15 contains ITZ 
at 30% loading and HPMCP at 40% (w/w), so the hydrogen bonding effect was most noticeable 
in this sample.  The ability of polymers to interact with the API at a molecular level has a 
significant influence on the properties of the solid dispersions because the intermolecular forces 
between the components will stabilise the amorphous drug both during storage and whilst 
maintaining supersaturation in solution. 
3.7. ssNMR analysis 
ssNMR is non-destructive technique which provides qualitative and quantitative information 
about amorphous solid dispersions. The ssNMR results are shown in the supplementary data 
(SD2).  The 13C ssNMR spectrum of crystalline ITZ is consistent with that previously published 
in the literature (Shevchenko et al., 2013; Van Eerdenbrugh et al., 2009). A broadening of peaks 
was noted in the spectrum of the ASD, indicating that the components were amorphous. In the 
NMR spectrum of crystalline ITZ (ASD 17), narrow and sharp peaks are present; these are 
particularly absent in the 13C NMR spectrum of the ASD.  Differences between the amorphous 
and crystalline ITZ can be most obviously seen around 152 ppm (one peak for amorphous ITZ in 
the ASD; three peaks for crystalline ITZ), 146 ppm (one peak for amorphous ITZ in the ASD; 
two peaks for crystalline ITZ), and 108 ppm (one peak in the ASD; crystalline: two peaks).  
Multiple peaks from the HPMCP and Soluplus® excipients overlapped with those from the spectra 
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of the ASD. Broad peaks with chemical shift(s) nearly matching to those of crystalline ITZ in the 
13C NMR spectrum of the ASD confirm that the ITZ is amorphous.  These results are consistent 
with the powder X-ray diffraction and DSC studies. 
3.8.  In-vitro dissolution 
Following HPLC method development, quantification of ITZ was possible from nanogram to 
microgram levels in various pharmaceutical compositions. To fully assess the performance of the 
method, validation was performed according to the International Conference on Harmonization 
(ICH) guidelines (ICH, 1997). Several blank measurements were performed during the course of 
analysis so that average blank responses could be subtracted from the tested samples. Polymers 
did not interfere with the elution time of ITZ, which was detected at a retention time equivalent 
to 8.8 min. All samples eluted with a retention time difference of ≤ 3% relative to reference 
standards. Linearity within the range of 15.63 µg/mL to 244 ng/mL was excellent with seven 
concentration points, each assayed in triplicate, showing square correlation coefficient (R2) = 
0.999. Precision data for this assessment included calculation of the relative standard deviation 
(%RSD) of peak area for each of the seven concentration points for three replicated ITZ injections 
and was found to be equal to or less than 0.78%.  The limit of detection (LOD) and the limit of 
quantification (LOQ) were calculated on the basis of the standard deviation of the response and 
the slope obtained from the linearity plot as described in the relevant ICH guideline (ICH, 1997). 
LOD and LOQ of ITZ were found to be 67.8 ng/mL and 205.5 ng/mL respectively. LOD and 
LOQ were calculated as 3.3 α/S and 10 α/S respectively, where α is the standard deviation of the 
y-intercept and S is the slope of the regression line.  Results and a statistical analysis of the data 
suggested that the method is sensitive, selective, reproducible and more precise than the method 
previously used to measure ITZ (Davis et al., 2017). Thus, it could be effectively utilized for the 
routine estimation of the ITZ in various pharmaceutical ASD compositions. For the dissolution 
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studies, it can be seen in Figure 6 that the dissolution of ITZ exhibited a higher release profile 
from the processed ASDs relative to the crystalline API with ASDs concentration ten-fold higher 
than crystalline ITZ. While better than crystalline ITZ, the dissolution profiles were relatively low 
in comparison to a number of other formulations in acidic media and those determined in our 
previous study. It is likely that the release rate is related to the particle size of the milled extrudate 
and that the smaller particles prepared by spray drying would achieve faster dissolution (Davis et 
al., 2017). The release profiles for selected formulations are presented in Figure 6 showing the 
comparatively slow and low dissolution efficiency with drug release reaching ∼45% after 6 h in 
the best case. The dissolution profiles found in this study are very similar to that for the marketed 
drug Sporanox® (capsules contain a solid solution of ITZ and hypromellose that is coated on sugar 
beads produced by Janssen, Belgium). Also, to other formulations containing ITZ and Soluplus® 
prepared by Thiry and co-workers, however, it is worth mentioning that the extrudates were not 
milled (Thiry et al., 2017). Zhong and co-authors indicated that dissolution of Sporanox® and 
other ITZ/Soluplus® formulations prepared by HME can reach up to 80% in 60 min at pH 1.2 
(Zhong et al., 2016). However, formulations containing ITZ/HPMC had a range of release profiles 
between 40 to 90% depending on the drug to polymer ratio; the higher the drug content, the lower 
the release (Six et al., 2001).  So, the relatively slow release reported here can be attributed to the 
particle size of the milled extrudate and the insolubility of HPMCP at gastric pH. The formulations 
could be optimized by milling to a smaller particle size distribution or designed to pass through 
the stomach and release the drug in small intestine. However, this requires further investigation 
and can be considered for future work. 
4. Concluding Remarks 
ITZ-HPMCP-Soluplus® ternary solid dispersions were successfully developed using HME and 
significantly enhanced the solubility and bioavailability of ITZ, a poorly water-soluble drug, while 
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maintaining excellent physical stability. A DoE approach was employed to minimize the number 
of experiments and provide a systematic way of selecting the drug-polymer ratios; drug loading 
ranged from 10 – 30% (w/w) and HPMCP/Soluplus® ratios varied from 30 – 60%.  All 
formulations remained PXRD amorphous after 12 months of storage at 25°C and 50% RH 
indicating the excellent stability of the formulations, which is likely due to intermolecular 
interactions between HPMCP/Soluplus® and ITZ.  The DSC scans for ITZ formulations showed 
that for each formulation, a single glass transition value regardless of the ratio was measured 
indicating that the ASDs are present as a homogenous single phase. A new HPLC method was 
developed in this study, which allows for the accurate quantification of ITZ in solution along with 
HPMCP and Soluplus®. The dissolution of ITZ formulations exhibited higher release profiles than 
the crystalline API with ASDs concentration ten-fold higher than crystalline ITZ. While FTIR 
was effectively used to determine the molecular interactions between the ITZ and 
polymers, there is a possibility for future research to distinguish the interactions in binary 
systems and quantify such interactions with advanced analytical tools such as solid state 
NMR. 
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Figure    1: Chemical structures of Itraconazole, HPMCP and Soluplus®.     
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Figure    2: A mixture (user-defined) design space. Example: selected circled point corresponds to a composition of 10:60:30; 
ITZ:HPMCP:Soluplus® (Run 11 in Table 1). 
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Figure   3: X-ray diffraction patterns of individual components and selected ITZ-HMPCP/Soluplus® compositions prepared by the 16mm extruder 
@ 160°C. 
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Figure    4: DSC thermograms of crystalline ITZ, quench cooled ITZ, Soluplus® and HPMCP in the powder form and extruded ASDs. 
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Figure    5: FTIR spectroscopy spectra of crystalline ITZ, Soluplus® and HPMCP and selected ASD (no. 17: containing 30% ITZ, 30% HPMCP 
and 40 Soluplus). 
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Figure    6: Dissolution profiles of selected ASDs and crystalline ITZ in simulated gastric fluid, pH 1.2.  
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Table 1: Glass transition temperatures for ITZ/HMPCP/Soluplus® ASDs prepared by HME. 
Sample 
ID 
ITZ Soluplus HMPCP Tg, mix predicted by 
C-K equation (°C) 
Measured Tg  °C) 
1.  0.25 0.40 0.35 101.1 96.6 
2.  0.25 0.35 0.40 104.4 95.6 
3.  0.20 0.35 0.45 109.4 94.7 
4.  0.20 0.40 0.40 106.2 94.8 
5.  0.20 0.45 0.35 102.8 94.9 
6.  0.15 0.425 0.425 109.6 97.4 
7.  0.10 0.45 0.45 113.1 97.3 
8.  0.15 0.35 0.50 114.4 99.4 
9.  0.25 0.375 0.375 102.8 96.3 
10.  0.20 0.50 0.30 99.4 93.5 
11.  0.10 0.60 0.30 102.9 99.4 
12.  0.15 0.50 0.35 104.6 94.2 
13.  0.20 0.30 0.50 112.5 101.8 
14.  0.10 0.30 0.60 122.4 108.3 
15.  0.30 0.30 0.40 102.7 93.0 
16.  0.30 0.35 0.35 99.5 92.1 
17.  0.30 0.40 0.30 96.1 89.4 
C-K: Couchman–Karasz; ITZ: Itraconazole; HPMCP: Hydroxy propyl methyl cellulose phthalate. 
 
